
簡要描述:Adriamycin 23214-92-8Doxorubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of doxorubicin is as a Topoisomerase Inhibitor.
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 23214-92-8 |
|---|---|---|---|
| 分子式 | C27H29NO11 | 純度 | 98% |
| 分子量 | 543.52 | 貨號 | abs47027704 |
| 規(guī)格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | is an Anthracycline Topoisomerase Inhibi | 應用領域 | 化工,生物產業(yè),農林牧漁,制藥/生物制藥,綜合 |
Adriamycin 23214-92-8
| 產品描述 | |
| 描述 | Doxorubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of doxorubicin is as a Topoisomerase Inhibitor. The chemical classification of doxorubicin is Anthracyclines. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for three years(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 阿mei素;多柔bi星;Doxorubicin |
| 外觀 | Orange to red powder |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| In vitro(體外研究) | Combination of Doxorubicin and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells. |
| In vivo(體內研究) | Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3. |
| 研究領域 | |
| 研究領域 | CancerTumor biomarkers CancerTumor immunology MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
